New kidney cancer drug shows promise in early safety trial
NCT ID NCT04846920
First seen May 24, 2026 · Last updated May 24, 2026
Summary
This early-stage study tested the safety of a drug called belzutifan in 29 adults with advanced clear cell kidney cancer that had worsened after other treatments. The main goal was to see if different doses were safe and tolerable. Researchers monitored side effects and how the drug moved through the body to find the best dose for future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, RENAL CELL are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beth Israel Deaconess Medical Center ( Site 1002)
Boston, Massachusetts, 02215, United States
-
University of Michigan ( Site 1006)
Ann Arbor, Michigan, 48109, United States
-
University of Texas MD Anderson Cancer Center-Genitourinary Medical Oncology ( Site 1007)
Houston, Texas, 77030, United States
-
Vanderbilt University Medical Center-Vanderbilt-Ingram Cancer Center ( Site 1005)
Nashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.